Skip to main content
Erschienen in: International Journal of Hematology 3/2013

01.09.2013 | Progress in Hematology

Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses

verfasst von: Yoshinobu Maeda

Erschienen in: International Journal of Hematology | Ausgabe 3/2013

Einloggen, um Zugang zu erhalten

Abstract

In addition to reduced-intensity conditioning, which has expanded the eligibility for hematopoietic cell transplantation (HCT) to older patients, increased availability of alternative donors, including HLA-mismatched unrelated donors, has increased access to allogeneic HCT for more patients. However, acute graft-versus-host disease (GVHD) remains a lethal complication, even in HLA-matched donor–recipient pairs. The pathophysiology of GVHD depends on aspects of adaptive immunity and interactions between donor T-cells and host dendritic cells (DCs). Recent work has revealed that the role of other immune cells and endothelial cells and components of the innate immune response are also important. Tissue damage caused by the conditioning regimen leads to the release of exogenous and endogenous “danger signals”. Exogenous danger signals called pathogen-associated molecular patterns and endogenous noninfectious molecules known as damage-associated molecular patterns (DAMPs) are responsible for initiating or amplifying acute GVHD by enhancing DC maturation and alloreactive T-cell responses. A significant association of innate immune receptor polymorphisms with outcomes, including GVHD severity, was observed in patients receiving allogeneic HCT. Understanding of the role of innate immunity in acute GVHD might offer new therapeutic approaches.
Literatur
1.
Zurück zum Zitat Barnes DW, Loutit JF, Micklem HS. “Secondary disease” of radiation chimeras: a syndrome due to lymphoid aplasia. Ann NY Acad Sci. 1962;99:374–85.PubMedCrossRef Barnes DW, Loutit JF, Micklem HS. “Secondary disease” of radiation chimeras: a syndrome due to lymphoid aplasia. Ann NY Acad Sci. 1962;99:374–85.PubMedCrossRef
2.
Zurück zum Zitat Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMed Billingham RE. The biology of graft-versus-host reactions. Harvey Lect. 1966;62:21–78.PubMed
3.
Zurück zum Zitat Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.PubMedCrossRef Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science. 1999;285:412–5.PubMedCrossRef
4.
Zurück zum Zitat Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8.PubMed Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172:7393–8.PubMed
5.
Zurück zum Zitat Levine JE. Implications of TNF-alpha in the pathogenesis and management of GVHD. Int J Hematol. 2011;93:571–7.PubMedCrossRef Levine JE. Implications of TNF-alpha in the pathogenesis and management of GVHD. Int J Hematol. 2011;93:571–7.PubMedCrossRef
6.
Zurück zum Zitat Shin OS, Harris JB. Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD. Korean J Hematol. 2011;46:69–79.PubMedCrossRef Shin OS, Harris JB. Innate immunity and transplantation tolerance: the potential role of TLRs/NLRs in GVHD. Korean J Hematol. 2011;46:69–79.PubMedCrossRef
7.
Zurück zum Zitat Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–91.PubMedCrossRef Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102:1882–91.PubMedCrossRef
8.
Zurück zum Zitat Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581–9.PubMedCrossRef Cooke KR, Gerbitz A, Crawford JM, et al. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest. 2001;107:1581–9.PubMedCrossRef
9.
Zurück zum Zitat Garantziotis S, Palmer SM, Snyder LD, et al. Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide. Transplantation. 2007;84:1012–9.PubMedCrossRef Garantziotis S, Palmer SM, Snyder LD, et al. Alloimmune lung injury induced by local innate immune activation through inhaled lipopolysaccharide. Transplantation. 2007;84:1012–9.PubMedCrossRef
10.
Zurück zum Zitat Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:384–7.PubMedCrossRef Lorenz E, Schwartz DA, Martin PJ, et al. Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:384–7.PubMedCrossRef
11.
Zurück zum Zitat Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation. 2006;81:247–54.PubMedCrossRef Elmaagacli AH, Koldehoff M, Hindahl H, et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation. 2006;81:247–54.PubMedCrossRef
12.
Zurück zum Zitat Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T-cells to peripheral tissues. J Exp Med. 2006;203:2021–31.PubMedCrossRef Chakraverty R, Cote D, Buchli J, et al. An inflammatory checkpoint regulates recruitment of graft-versus-host reactive T-cells to peripheral tissues. J Exp Med. 2006;203:2021–31.PubMedCrossRef
13.
Zurück zum Zitat Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008;112:3508–16.PubMedCrossRef Taylor PA, Ehrhardt MJ, Lees CJ, et al. TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. Blood. 2008;112:3508–16.PubMedCrossRef
14.
Zurück zum Zitat Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111:3257–65.PubMedCrossRef Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2008;111:3257–65.PubMedCrossRef
15.
Zurück zum Zitat Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood. 2009;114:5062–70.PubMedCrossRef Jasperson LK, Bucher C, Panoskaltsis-Mortari A, et al. Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood. 2009;114:5062–70.PubMedCrossRef
16.
Zurück zum Zitat Crellin NK, Garcia RV, Hadisfar O, et al. Human CD4+ T-cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+ CD25+ T regulatory cells. J Immunol. 2005;175:8051–9.PubMed Crellin NK, Garcia RV, Hadisfar O, et al. Human CD4+ T-cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+ CD25+ T regulatory cells. J Immunol. 2005;175:8051–9.PubMed
17.
Zurück zum Zitat Galkin VE, Yu X, Bielnicki J, et al. Divergence of quaternary structures among bacterial flagellar filaments. Science. 2008;320:382–5.PubMedCrossRef Galkin VE, Yu X, Bielnicki J, et al. Divergence of quaternary structures among bacterial flagellar filaments. Science. 2008;320:382–5.PubMedCrossRef
18.
Zurück zum Zitat Hossain MS, Jaye DL, Pollack BP, et al. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. J Immunol. 2011;187:5130–40.PubMedCrossRef Hossain MS, Jaye DL, Pollack BP, et al. Flagellin, a TLR5 agonist, reduces graft-versus-host disease in allogeneic hematopoietic stem cell transplantation recipients while enhancing antiviral immunity. J Immunol. 2011;187:5130–40.PubMedCrossRef
19.
Zurück zum Zitat Calcaterra C, Sfondrini L, Rossini A, et al. Critical role of TLR9 in acute graft-versus-host disease. J Immunol. 2008;181:6132–9.PubMed Calcaterra C, Sfondrini L, Rossini A, et al. Critical role of TLR9 in acute graft-versus-host disease. J Immunol. 2008;181:6132–9.PubMed
20.
Zurück zum Zitat Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut. 2010;59:1079–87.PubMedCrossRef Heimesaat MM, Nogai A, Bereswill S, et al. MyD88/TLR9 mediated immunopathology and gut microbiota dynamics in a novel murine model of intestinal graft-versus-host disease. Gut. 2010;59:1079–87.PubMedCrossRef
21.
Zurück zum Zitat Elmaagacli AH, Koldehoff M, Beelen DW. Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. Bone Marrow Transplant. 2009;44:295–302.PubMedCrossRef Elmaagacli AH, Koldehoff M, Beelen DW. Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9. Bone Marrow Transplant. 2009;44:295–302.PubMedCrossRef
22.
Zurück zum Zitat Penack O, Smith OM, Cunningham-Bussel A, et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med. 2009;206:2101–10.PubMedCrossRef Penack O, Smith OM, Cunningham-Bussel A, et al. NOD2 regulates hematopoietic cell function during graft-versus-host disease. J Exp Med. 2009;206:2101–10.PubMedCrossRef
23.
Zurück zum Zitat Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008;118:545–59.PubMed Watanabe T, Asano N, Murray PJ, et al. Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis. J Clin Invest. 2008;118:545–59.PubMed
24.
Zurück zum Zitat Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800–8.PubMedCrossRef Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol. 2004;5:800–8.PubMedCrossRef
25.
Zurück zum Zitat Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004;104:889–94.PubMedCrossRef Holler E, Rogler G, Herfarth H, et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood. 2004;104:889–94.PubMedCrossRef
26.
Zurück zum Zitat Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood. 2006;107:4189–93.PubMedCrossRef Holler E, Rogler G, Brenmoehl J, et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood. 2006;107:4189–93.PubMedCrossRef
27.
Zurück zum Zitat Granell M, Urbano-Ispizua A, Arostegui JI, et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica. 2006;91:1372–6.PubMed Granell M, Urbano-Ispizua A, Arostegui JI, et al. Effect of NOD2/CARD15 variants in T-cell depleted allogeneic stem cell transplantation. Haematologica. 2006;91:1372–6.PubMed
28.
Zurück zum Zitat Mayor NP, Shaw BE, Hughes DA, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol. 2007;25:4262–9.PubMedCrossRef Mayor NP, Shaw BE, Hughes DA, et al. Single nucleotide polymorphisms in the NOD2/CARD15 gene are associated with an increased risk of relapse and death for patients with acute leukemia after hematopoietic stem-cell transplantation with unrelated donors. J Clin Oncol. 2007;25:4262–9.PubMedCrossRef
29.
Zurück zum Zitat Sairafi D, Uzunel M, Remberger M, et al. No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant. 2008;41:961–4.PubMedCrossRef Sairafi D, Uzunel M, Remberger M, et al. No impact of NOD2/CARD15 on outcome after SCT. Bone Marrow Transplant. 2008;41:961–4.PubMedCrossRef
30.
Zurück zum Zitat Gruhn B, Intek J, Pfaffendorf N, et al. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2009;15:1571–7.PubMedCrossRef Gruhn B, Intek J, Pfaffendorf N, et al. Polymorphism of interleukin-23 receptor gene but not of NOD2/CARD15 is associated with graft-versus-host disease after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant. 2009;15:1571–7.PubMedCrossRef
31.
Zurück zum Zitat Tanabe T, Yamaguchi N, Matsuda K, et al. Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population. Int J Hematol. 2011;93:771–8.PubMedCrossRef Tanabe T, Yamaguchi N, Matsuda K, et al. Association analysis of the NOD2 gene with susceptibility to graft-versus-host disease in a Japanese population. Int J Hematol. 2011;93:771–8.PubMedCrossRef
32.
Zurück zum Zitat Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010;115:1865–72.PubMedCrossRef Penack O, Holler E, van den Brink MR. Graft-versus-host disease: regulation by microbe-associated molecules and innate immune receptors. Blood. 2010;115:1865–72.PubMedCrossRef
33.
Zurück zum Zitat Wilhelm K, Ganesan J, Muller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16:1434–8.PubMedCrossRef Wilhelm K, Ganesan J, Muller T, et al. Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010;16:1434–8.PubMedCrossRef
34.
Zurück zum Zitat Tsukamoto H, Chernogorova P, Ayata K, et al. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood. 2012;119:4554–64.PubMedCrossRef Tsukamoto H, Chernogorova P, Ayata K, et al. Deficiency of CD73/ecto-5′-nucleotidase in mice enhances acute graft-versus-host disease. Blood. 2012;119:4554–64.PubMedCrossRef
35.
Zurück zum Zitat Lappas CM, Liu PC, Linden J, et al. Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol. 2010;87:345–54.PubMedCrossRef Lappas CM, Liu PC, Linden J, et al. Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol. 2010;87:345–54.PubMedCrossRef
36.
Zurück zum Zitat Granell M, Urbano-Ispizua A, Pons A, et al. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood. 2008;112:4337–42.PubMedCrossRef Granell M, Urbano-Ispizua A, Pons A, et al. Common variants in NLRP2 and NLRP3 genes are strong prognostic factors for the outcome of HLA-identical sibling allogeneic stem cell transplantation. Blood. 2008;112:4337–42.PubMedCrossRef
37.
Zurück zum Zitat Lee KH, Park SS, Kim I, et al. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Haematologica. 2007;92:651–7.PubMedCrossRef Lee KH, Park SS, Kim I, et al. P2X7 receptor polymorphism and clinical outcomes in HLA-matched sibling allogeneic hematopoietic stem cell transplantation. Haematologica. 2007;92:651–7.PubMedCrossRef
38.
Zurück zum Zitat Brennan TV, Lin L, Huang X, et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012;120:2899–908.PubMedCrossRef Brennan TV, Lin L, Huang X, et al. Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. Blood. 2012;120:2899–908.PubMedCrossRef
39.
Zurück zum Zitat Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA. 2012;109:564–9.PubMedCrossRef Tawara I, Sun Y, Lewis EC, et al. Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci USA. 2012;109:564–9.PubMedCrossRef
40.
Zurück zum Zitat Marcondes AM, Li X, Tabellini L, et al. Inhibition of IL-32 activation by alpha-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 2011;118:5031–9.PubMedCrossRef Marcondes AM, Li X, Tabellini L, et al. Inhibition of IL-32 activation by alpha-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood. 2011;118:5031–9.PubMedCrossRef
41.
Zurück zum Zitat Jarvis M, Marzolini M, Wang XN, et al. Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease. Transplantation. 2003;76:849–53.PubMedCrossRef Jarvis M, Marzolini M, Wang XN, et al. Heat shock protein 70: correlation of expression with degree of graft-versus-host response and clinical graft-versus-host disease. Transplantation. 2003;76:849–53.PubMedCrossRef
42.
Zurück zum Zitat Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation. 2005;79:815–20.PubMedCrossRef Bogunia-Kubik K, Lange A. HSP70-hom gene polymorphism in allogeneic hematopoietic stem-cell transplant recipients correlates with the development of acute graft-versus-host disease. Transplantation. 2005;79:815–20.PubMedCrossRef
43.
Zurück zum Zitat Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21.PubMedCrossRef Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21.PubMedCrossRef
44.
Zurück zum Zitat Brunner AM, Thomas R. Spitzer TR, Chen Yi-Bin A et al. Urate Oxidase (Rasburicase) to Inhibit Graft Versus Host Disease (GVHD) After Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT). ASH (Annual Meeting Abstracts) 2012;120: Abstract 3063. Brunner AM, Thomas R. Spitzer TR, Chen Yi-Bin A et al. Urate Oxidase (Rasburicase) to Inhibit Graft Versus Host Disease (GVHD) After Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation (HCT). ASH (Annual Meeting Abstracts) 2012;120: Abstract 3063.
45.
Zurück zum Zitat Milinkovic M, Antin JH, Hergrueter CA, et al. CD44– hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood. 2004;103:740–2.PubMedCrossRef Milinkovic M, Antin JH, Hergrueter CA, et al. CD44– hyaluronic acid interactions mediate shear-resistant binding of lymphocytes to dermal endothelium in acute cutaneous GVHD. Blood. 2004;103:740–2.PubMedCrossRef
46.
Zurück zum Zitat Shirali AC, Goldstein DR. Activation of the innate immune system by the endogenous ligand hyaluronan. Curr Opin Organ Transplant. 2008;13:20–5.PubMedCrossRef Shirali AC, Goldstein DR. Activation of the innate immune system by the endogenous ligand hyaluronan. Curr Opin Organ Transplant. 2008;13:20–5.PubMedCrossRef
47.
Zurück zum Zitat Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–66.PubMedCrossRef Ehrchen JM, Sunderkotter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86:557–66.PubMedCrossRef
48.
Zurück zum Zitat Chiusolo P, Giammarco S, Fanali C, et al. Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:888–92.PubMedCrossRef Chiusolo P, Giammarco S, Fanali C, et al. Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19:888–92.PubMedCrossRef
49.
Zurück zum Zitat Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res. 2011;343:189–99.PubMedCrossRef Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res. 2011;343:189–99.PubMedCrossRef
50.
Zurück zum Zitat Kornblit B, Masmas T, Petersen SL, et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:239–52.PubMedCrossRef Kornblit B, Masmas T, Petersen SL, et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010;16:239–52.PubMedCrossRef
51.
Zurück zum Zitat Inoue Y, Kosugi S, Miura I, et al. Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res. 2011;127:603–4.PubMedCrossRef Inoue Y, Kosugi S, Miura I, et al. Successful treatment of refractory acute GVHD complicated by severe intestinal transplant-associated thrombotic microangiopathy using recombinant thrombomodulin. Thromb Res. 2011;127:603–4.PubMedCrossRef
52.
Zurück zum Zitat Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92.PubMedCrossRef Luft T, Dietrich S, Falk C, et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118:1685–92.PubMedCrossRef
53.
Zurück zum Zitat Fuchs TA, Kremer Hovinga JA, Schatzberg D et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012;120:1157–1164. Fuchs TA, Kremer Hovinga JA, Schatzberg D et al. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood 2012;120:1157–1164.
Metadaten
Titel
Pathogenesis of graft-versus-host disease: innate immunity amplifying acute alloimmune responses
verfasst von
Yoshinobu Maeda
Publikationsdatum
01.09.2013
Verlag
Springer Japan
Erschienen in
International Journal of Hematology / Ausgabe 3/2013
Print ISSN: 0925-5710
Elektronische ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-013-1421-x

Weitere Artikel der Ausgabe 3/2013

International Journal of Hematology 3/2013 Zur Ausgabe

Kuratives Potenzial von CAR-T-Zellen bei r/r LBCL untermauert

15.06.2024 ASCO 2024 Kongressbericht

Auch nach längerem Follow-up sind CAR-T-Zellen weiter wirksam. Das zeigt eine Studie mit Lisocabtagen-Maraleucel als Zweitlinientherapie bei Personen mit primär refraktärem oder früh rezidiviertem großzelligem B-Zell-Lymphom (r/r LBCL). Sie wurden bei der ASCO-Tagung vorgestellt.

"Limited stage" SCLC: Konsolidierung schenkt Lebensjahre

14.06.2024 ASCO 2024 Kongressbericht

Standardtherapie bei einem inoperablen kleinzelligen Lungenkarzinom im Stadium I-III (LS-SCLC) ist die Radiochemotherapie. Eine anschließende Konsolidierung mit Durvalumab kann das mediane Überleben um fast zwei Jahre verlängern.

Fortgeschrittenes Ovarial-Ca.: Unverdächtige Lymphknoten entfernen?

13.06.2024 ASCO 2024 Kongressbericht

Beim fortgeschrittenen Ovarialkarzinom und klinisch verdächtigen Lymphknoten in der Debulking-Op. ist die abdominale retroperitoneale Lymphadenektomie (RPL) Standard. Ohne verdächtige Lymphknoten ist der Nutzen fraglich.

Myasthenia gravis durch Krebsimmuntherapie

13.06.2024 Myasthenia gravis Nachrichten

Sie sind sehr selten, können aber schwerwiegende Folgen haben: immunologische Nebenwirkungen unter Checkpointhemmern. Ein Behandlungsteam berichtet nun über einen Mann, der während einer Darmkrebsbehandlung eine Myasthenia gravis entwickelt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.